Abstract:Background: The pathogenesis of inflammatory bowel disease (IBD) involves the role of bacteria. These bacteria ferment nonstarch polysaccharides in the colon producing a fermentation profile that through altered gut permeability can be traced in urine. We proposed to track the resultant volatile organic compounds or gases that emanate from urine using noninvasive real-time tools, specifically by electronic nose and Field Asymmetric Ion Mobility Spectrometer (FAIMS) instruments. The aim of this study was to determine the utility of electronic nose and FAIMS instruments to detect and track the fermentation profile of patients with IBD.Methods: Sixty-two individuals were recruited, 48 individuals with IBD (24 with Crohn's disease and ulcerative colitis, respectively) and 14 controls. The disease activity was recorded, and urine samples were collected. The headspace (the air above the sample) was analyzed using the electronic nose and FAIMS instruments.Results: Electronic nose data analysis was conducted through (1) Principal Component Analysis (data were analyzed together without previous categorization); and (2) Discriminant Function Analysis (samples were precategorized [clinical groups]). The FAIMS data were processed by Fisher's Discriminant Analysis (precategorized [clinical groups]). Both technologies consistently showed the ability to separate those with IBD and controls with a > 75% accuracy; P < 0.001. In a smaller subgroup (n = 24), we also demonstrated that the electronic nose and FAIMS instruments can distinguish between active disease and those in remission.Conclusions: The fermentation profile or fermentome is disparate in those with IBD compared with controls-a reflection of the bacterial diversity in health and disease. This profile also changes (and was tracked) as the disease is induced into remission. Thus, the electronic nose and FAIMS instruments offer the potential of a noninvasive real-time diagnostic tool for point of care clinical use.

Orally Administered Platinum Nanomarkers for Urinary Monitoring of Inflammatory Bowel Disease

Refining Nanoprobes for Monitoring of Inflammatory Bowel Disease

Dual-Locked Chemiluminescent Probe Enables Precise Imaging and Timely Diagnosis of Colitis Via Chymotrypsin/Vanin-1 Cascade Activation

Advances in Macrophage-Targeting Nanoparticles for the Diagnosis and Treatment of Inflammatory Bowel Disease.

Oral enzyme-responsive nanoprobes for targeted theranostics of inflammatory bowel disease

Neutrophil Elastase-Activated Carbon Dots for Non-Invasive Early Diagnosis of Inflammatory Bowel Disease by Near-Infrared-ii Fluorescence Imaging

Nanoparticle-based Imaging of Inflammatory Bowel Disease.

Nanoparticle‐based imaging of inflammatory bowel disease

A Novel Tool For Noninvasive Diagnosis And Tracking Of Patients With Inflammatory Bowel Disease

Engineered calprotectin-sensing probiotics for IBD surveillance in humans

Renal clearable catalytic gold nanoclusters for in vivo disease monitoring

An AIEgen-based oral-administration nanosystem for detection and therapy of ulcerative colitis via 3D-MSOT/NIR-II fluorescent imaging and inhibiting NLRP3 inflammasome

A CRISPR mediated point‐of‐care assay for the detection of mucosal calprotectin in an animal model of ulcerative colitis

Hypoxia‐Responsive Platinum Supernanoparticles for Urinary Microfluidic Monitoring of Tumors

A CRISPR mediated point-of-care assay for the detection of mucosal calprotectin in an animal model of ulcerative colitis

Closed-loop theranostic microgels for immune microenvironment modulation and microbiota remodeling in ulcerative colitis

A Biomarker‐Responsive Nanosystem with Colon‐Targeted Delivery for Ulcerative Colitis's Detection and Treatment with Optoacoustic/NIR‐II Fluorescence Imaging

Ultrasensitive Urinary Diagnosis of Organ Injuries Using Time-Resolved Luminescent Lanthanide Nano-bioprobes

Molecular Engineering of Activatable NIR-II Hemicyanine Reporters for Early Diagnosis and Prognostic Assessment of Inflammatory Bowel Disease

A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease

Impact of administration route on nanocarrier biodistribution in a murine colitis model